Cargando…

Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study

INTRODUCTION: Patients with cardiogenic shock (CS) are at a high risk of developing infectious complications; however, their early detection is difficult, mainly due to a frequently occurring noninfectious inflammatory response, which accompanies an extensive myocardial infarction (MI) or a postcard...

Descripción completa

Detalles Bibliográficos
Autores principales: Parenica, Jiri, Jarkovsky, Jiri, Malaska, Jan, Mebazaa, Alexandre, Gottwaldova, Jana, Helanova, Katerina, Litzman, Jiri, Dastych, Milan, Tomandl, Josef, Spinar, Jindrich, Dostalova, Ludmila, Lokaj, Petr, Tomandlova, Marie, Pavkova, Monika Goldergova, Sevcik, Pavel, Legrand, Matthieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266423/
https://www.ncbi.nlm.nih.gov/pubmed/27749762
http://dx.doi.org/10.1097/SHK.0000000000000756
_version_ 1782500468654604288
author Parenica, Jiri
Jarkovsky, Jiri
Malaska, Jan
Mebazaa, Alexandre
Gottwaldova, Jana
Helanova, Katerina
Litzman, Jiri
Dastych, Milan
Tomandl, Josef
Spinar, Jindrich
Dostalova, Ludmila
Lokaj, Petr
Tomandlova, Marie
Pavkova, Monika Goldergova
Sevcik, Pavel
Legrand, Matthieu
author_facet Parenica, Jiri
Jarkovsky, Jiri
Malaska, Jan
Mebazaa, Alexandre
Gottwaldova, Jana
Helanova, Katerina
Litzman, Jiri
Dastych, Milan
Tomandl, Josef
Spinar, Jindrich
Dostalova, Ludmila
Lokaj, Petr
Tomandlova, Marie
Pavkova, Monika Goldergova
Sevcik, Pavel
Legrand, Matthieu
author_sort Parenica, Jiri
collection PubMed
description INTRODUCTION: Patients with cardiogenic shock (CS) are at a high risk of developing infectious complications; however, their early detection is difficult, mainly due to a frequently occurring noninfectious inflammatory response, which accompanies an extensive myocardial infarction (MI) or a postcardiac arrest syndrome. The goal of our prospective study was to describe infectious complications in CS and the immune/inflammatory response based on a serial measurement of several blood-based inflammatory biomarkers. METHODS: Eighty patients with CS were evaluated and their infections were monitored. Inflammatory markers (C-reactive protein, procalcitonin, pentraxin 3, presepsin) were measured seven times per week. The control groups consisted of 11 patients with ST segment elevation myocardial infarction without CS and without infection, and 22 patients in septic shock. RESULTS: Infection was diagnosed in 46.3% of patients with CS; 16 patients developed an infection within 48 h. Respiratory infection was most common, occurring in 33 out of 37 patients. Infection was a significant or even the main reason of death only in 3.8% of all patients with CS, and we did not find statistically significant difference in 3-month mortality between group of patients with CS with and without infection. There was no statistically significant prolongation of the duration of mechanical ventilation associated with infection. Strong inflammatory response is often in patients with CS due to MI, but we found no significant difference in the course of the inflammatory response expressed by evaluated biomarkers in patients with CS with and without infection. We found a strong relationship between the elevated inflammatory markers (sampled at 12 h) and the 3-month mortality: the area under the curve of receiver operating characteristic ranged between 0.683 and 0.875. CONCLUSION: The prevalence of infection in patients with CS was 46.3%, and respiratory tract infections were the most common type. Infections did not prolong statistically significantly the duration of mechanical ventilation and did not increase the prevalence of hospital mortality in this high-risk CS population. CS due to acute myocardial infarction was accompanied by a strong and highly variable inflammatory response, but it did not reach the intensity of the inflammatory response observed in patients with septic shock. An extensive immune/inflammatory response in patients with CS is linked to a poor prognosis.
format Online
Article
Text
id pubmed-5266423
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-52664232017-02-08 Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study Parenica, Jiri Jarkovsky, Jiri Malaska, Jan Mebazaa, Alexandre Gottwaldova, Jana Helanova, Katerina Litzman, Jiri Dastych, Milan Tomandl, Josef Spinar, Jindrich Dostalova, Ludmila Lokaj, Petr Tomandlova, Marie Pavkova, Monika Goldergova Sevcik, Pavel Legrand, Matthieu Shock Clinical Aspects INTRODUCTION: Patients with cardiogenic shock (CS) are at a high risk of developing infectious complications; however, their early detection is difficult, mainly due to a frequently occurring noninfectious inflammatory response, which accompanies an extensive myocardial infarction (MI) or a postcardiac arrest syndrome. The goal of our prospective study was to describe infectious complications in CS and the immune/inflammatory response based on a serial measurement of several blood-based inflammatory biomarkers. METHODS: Eighty patients with CS were evaluated and their infections were monitored. Inflammatory markers (C-reactive protein, procalcitonin, pentraxin 3, presepsin) were measured seven times per week. The control groups consisted of 11 patients with ST segment elevation myocardial infarction without CS and without infection, and 22 patients in septic shock. RESULTS: Infection was diagnosed in 46.3% of patients with CS; 16 patients developed an infection within 48 h. Respiratory infection was most common, occurring in 33 out of 37 patients. Infection was a significant or even the main reason of death only in 3.8% of all patients with CS, and we did not find statistically significant difference in 3-month mortality between group of patients with CS with and without infection. There was no statistically significant prolongation of the duration of mechanical ventilation associated with infection. Strong inflammatory response is often in patients with CS due to MI, but we found no significant difference in the course of the inflammatory response expressed by evaluated biomarkers in patients with CS with and without infection. We found a strong relationship between the elevated inflammatory markers (sampled at 12 h) and the 3-month mortality: the area under the curve of receiver operating characteristic ranged between 0.683 and 0.875. CONCLUSION: The prevalence of infection in patients with CS was 46.3%, and respiratory tract infections were the most common type. Infections did not prolong statistically significantly the duration of mechanical ventilation and did not increase the prevalence of hospital mortality in this high-risk CS population. CS due to acute myocardial infarction was accompanied by a strong and highly variable inflammatory response, but it did not reach the intensity of the inflammatory response observed in patients with septic shock. An extensive immune/inflammatory response in patients with CS is linked to a poor prognosis. Lippincott Williams & Wilkins 2017-02 2017-01-13 /pmc/articles/PMC5266423/ /pubmed/27749762 http://dx.doi.org/10.1097/SHK.0000000000000756 Text en Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Shock Society. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Clinical Aspects
Parenica, Jiri
Jarkovsky, Jiri
Malaska, Jan
Mebazaa, Alexandre
Gottwaldova, Jana
Helanova, Katerina
Litzman, Jiri
Dastych, Milan
Tomandl, Josef
Spinar, Jindrich
Dostalova, Ludmila
Lokaj, Petr
Tomandlova, Marie
Pavkova, Monika Goldergova
Sevcik, Pavel
Legrand, Matthieu
Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study
title Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study
title_full Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study
title_fullStr Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study
title_full_unstemmed Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study
title_short Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study
title_sort infectious complications and immune/inflammatory response in cardiogenic shock patients: a prospective observational study
topic Clinical Aspects
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266423/
https://www.ncbi.nlm.nih.gov/pubmed/27749762
http://dx.doi.org/10.1097/SHK.0000000000000756
work_keys_str_mv AT parenicajiri infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT jarkovskyjiri infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT malaskajan infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT mebazaaalexandre infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT gottwaldovajana infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT helanovakaterina infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT litzmanjiri infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT dastychmilan infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT tomandljosef infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT spinarjindrich infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT dostalovaludmila infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT lokajpetr infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT tomandlovamarie infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT pavkovamonikagoldergova infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT sevcikpavel infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy
AT legrandmatthieu infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy